Bristol Myers Squibb is storming ASCO 2025 with data from over 80 studies covering 20+ cancer types, showcasing its oncology ...

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

ZoomRx polled 50 experienced oncologists and hemato-oncologists about 20 cancer drugmakers, asking the doctors to rank the ...

The Food and Drug Administration (FDA) has approved the combination of nivolumab (Opdivo ®) plus ipilimumab (Yervoy ® ), both from Bristol Myers Squibb Company, as an option for first-line therapy for ...

Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded ...

Bristol Myers Squibb is gearing up for its moment in the spotlight at the Bernstein 41st Annual Strategic Decisions ...

BMSCH opens a Same Day Services center for kids needing infusion therapies, backed by a $2.5M gift from the Bristol Myers ...

The stock's fall snapped a four-day winning streak.

MIT researchers found a way to measure cell density quickly and accurately -- measuring up to 30,000 cells in a single hour.

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Bernstein 41 st Annual Strategic ...

Recent findings regarding interferon and Janus kinase inhibition may hold clues to improving outcomes in patients with ...